The FDA prescribing information for<unk>  (Ilaris) includes a warning for potential increased risk of serious infections due to IL-1 blockade. Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in people with rheumatic conditions, in particular Still's disease, and should be aggressively treated. Treatment with immunosuppressants may increase the risk of malignancies. People are advised not to receive live vaccinations during treatment.
Canakinumab
Anakinra
Sarilumab
Secukinumab
Anifrolumab
Emapalumab
Belatacept
Avelumab